ArticleCancer chemotherapy and pharmacology2025

Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).

Anuradha Krishnamurthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.